Related Experiment Video

Updated: Aug 12, 2026

Implantation of Total Artificial Heart in Congenital Heart Disease
07:27

Implantation of Total Artificial Heart in Congenital Heart Disease

Published on: July 18, 2014

Metoprolol CR/XL in the treatment of chronic heart failure

W A Gattis1

  • 1Duke University Medical Center, Durham, North Carolina 27705, USA.

Pharmacotherapy
|May 15, 2001
PubMed

Insights

Metoprolol CR/XL (metoprolol succinate extended-release tablets) significantly improved survival and reduced hospitalizations in heart failure patients. Individualized dosing and monitoring are crucial for optimizing outcomes with this beta-blocker.

Area of Science:

  • Cardiology
  • Pharmacology
  • Internal Medicine

Background:

  • Metoprolol CR/XL (metoprolol succinate extended-release tablets) is a selective beta1-adrenergic receptor antagonist.
  • Heart failure management often involves beta-blocker therapy to improve patient outcomes.
  • Previous studies have demonstrated benefits of beta-blockers in heart failure, but specific properties of extended-release formulations warrant attention.

Purpose of the Study:

  • To evaluate the efficacy of Metoprolol CR/XL in patients with New York Heart Association (NYHA) class II-IV heart failure.
  • To highlight the pharmacokinetic and pharmacodynamic differences between Metoprolol CR/XL and conventional metoprolol tartrate.
  • To emphasize the importance of individualized patient evaluation for optimal use of Metoprolol CR/XL in heart failure.

Main Methods:

  • A randomized clinical trial was conducted involving patients diagnosed with NYHA class II-IV heart failure.
  • The study assessed key outcomes including survival rates and hospitalization frequency.
  • Pharmacokinetic and pharmacodynamic profiles of Metoprolol CR/XL were compared to metoprolol tartrate.

Main Results:

  • Metoprolol CR/XL demonstrated a significant improvement in survival rates among the studied heart failure population.
  • Hospitalization rates were substantially reduced in patients treated with Metoprolol CR/XL.
  • Distinct pharmacokinetic and pharmacodynamic properties of Metoprolol CR/XL were identified, potentially influencing clinical application.

Conclusions:

  • Metoprolol CR/XL is an effective treatment for improving survival and reducing hospitalizations in patients with NYHA class II-IV heart failure.
  • Understanding the unique characteristics of Metoprolol CR/XL is essential for its appropriate clinical application.
  • Personalized patient assessment, including consideration of drug interactions and comorbidities, is vital for maximizing therapeutic benefits and ensuring patient safety.

More Related Videos

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment08:24

Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment

Published on: May 25, 2020

Related Concept Videos

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...